Sesenbio.com

Site Inspections

Overview & More informations

Sesen Bio (sesenbio.com) is clinical-stage biopharmaceutical company developing targeted fusion protein therapeutics for the treatment of cancer. The company's lead product candidate, Vicineum, is a Phase 3-ready antibody-drug conjugate (ADC) targeting Claudin 18.2, a protein overexpressed in multiple solid tumors, including gastric, pancreatic, and lung cancers. Sesen Bio's other product candidates include:

* VB6-844: A preclinical ADC targeting B7-H3, a protein overexpressed in various solid tumors.
* EDO-S101: A preclinical ADC targeting CD30, a protein expressed in hematologic malignancies.

The company uses its proprietary Fleximer™ technology platform to develop its ADCs. Fleximer™ is a next-generation linker technology that enables the precise and stable conjugation of cytotoxic payloads to antibodies. This technology allows Sesen Bio to develop ADCs with improved efficacy and safety profiles.

Sesen Bio is headquartered in Cambridge, Massachusetts. The company has a strong scientific team with expertise in antibody engineering, ADC development, and clinical research. The company is led by Dr. Thomas Cannell, a seasoned biotechnology executive with over 20 years of experience in the industry.

Sesen Bio is a promising clinical-stage biopharmaceutical company with a focus on developing targeted fusion protein therapeutics for the treatment of cancer. The company's lead product candidate, Vicineum, has the potential to be a best-in-class ADC for the treatment of Claudin 18.2-positive solid tumors. Sesen Bio's other product candidates and proprietary Fleximer™ technology platform also have the potential to generate value for shareholders.

Domains Expiration Date Updated